SG
EDIT icon

Societe Generale’s Editas Medicine EDIT Stock Holding History

Societe Generale’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$356K Buy
+14,597
New +$492K ﹤0.01% 1866

Other funds holding EDIT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FVFIGP
Flagship Ventures Fund IV General Partner Cambridge, Massachusetts $585M AUM
PVMCV
Polaris Venture Management Co VI Boston, Massachusetts $43.1M AUM 78.12% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Societe Generale's EDIT Position: Q2 2016 in Review

Societe Generale opened a new position in Editas Medicine (EDIT) in Q2 2016: 14,597 shares worth $356K. The stake represents ﹤0.01% of the portfolio and ranks #1866 among its holdings.

68 funds tracked by Wall St. Rank hold EDIT as of Q2 2016.

  • Societe Generale held 14,597 shares of Editas Medicine worth $356K as of Q2 2016.
  • Editas Medicine was a new Societe Generale position in Q2 2016.
  • Editas Medicine made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #1866 holding.
  • 68 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.